(RR) 7.88, 95% CI 4.10, 15.17, P < 0.0001; late: 8% vs 1% respectively, RR 9.96, 95% CI 1.88, 52.87, P ¼ 0.0081). Ab positivity was associated with abnormal NFC (P ¼ 0.025 for any Ab, P ¼ 0.019 for ANA, P < 0.001 for ACA). The RR of detecting a SSc NFC pattern (early/active/late) if ANA or ACA þve was 1.88 (1.16, 3.05, P ¼ 0.0067) and 2.59 (95% CI 1.80, 3.72, P < 0.001) respectively. A history of previous DU in sRP was also associated with abnormal NFC (P ¼ 0.015) and SSc NFC pattern (RR 2.59, 95% CI 1.70, 3.96, P ¼ 0.0037). Abþve with a SSc NFC pattern conferred an OR of SScsRP of 11.03 (95% CI 4.81, 25.77, P < 0.0001); early: 3.22 (95% CI 1.24, 8.15, P < 0.0119), active: 7.6 (95% CI 2.87, 20.56, P < 0.0001), late: 7.12 (95% CI 0.97, 80.25, P < 0.0273). Background: SSc is systemic CTDs, which is characterized by autoimmune disorders, disorders in microcirculation, inflammation and fibrosis of tissues and organs. It was proved that in pathogenesis of SSc are involved many cytokines, including IL-6. The aim of the study was to find association between concentration of IL-6 and the presence of pulmonary disorders confirmed in high resolution computer tomography (HRCT), which may be active (alveolitis) and inactive (without alveolitis), including type of the disease, the presence of markers of inflammation and abnormalities in serological parameters in patients with SSc. Methods: The study was performer in 66 patients with SSc (age 21-74 years), diagnosed on the basis of ARA criteria. Patients were divided into two groups according to the type of the disease: with limited (lSSc) and diffuse skin involvement (dSSc). There were 30 healthy volunteers in the control group. In both groups were determined concentrations of IL-6 using R&D Sytems tests. In patients with SSc were also performed ESR, CRP, fibrinogen, immunoglobulins of IgG, IgM and IgA classes, ANA, Scl-70, ACA and HRCT. Results: As the abnormal values of IL-6 were considered concentrations > 2.5 pg/ml. We found significant difference in IL-6 concentrations between patients with SSc and the control group (P < 0.0007). The analysis within the patients group showed significantly higher concentrations of IL-6 in dSSc in comparison with lSSc (P < 0.0344). The comparison between patients with both active and inactive disorders in lung and patients without pulmonary changes showed increased risk of interstitial lung disease development in patients with high concentration of IL-6 (OR 4.73; 95% CI: 1.28, 17.52). The risk of alveolitis development was the greatest (OR 5.42; 95% CI: 1.22, 23.97). There was also association between high concentration of IL-6 and CRP (OR 4.66; 95% CI: 1.24, 17.45). We found no association with the rest of analysed inflammatory markers and autoantibodies. Conclusion: There is significant association between high concentration of IL-6 and pulmonary disorders in the course of SSc. IL-6 as a proinflammatory factor might be early marker of ILD development in patients with SSc. Disclosure statement: The authors have declared no conflicts of interest. thickness (TSF) and mid-arm muscle circumference (MAMC), may be used for the early detection of malnutrition in a variety of disease groups. However, there is limited data on the role of anthropometry in conditions involving muscle and skin, such as SSc. Methods: Patients were studied in the outpatient department of a tertiary SSc centre. Demographics and disease characteristics were recorded. Weight, height, non-dominant mid-arm circumference and TSF were measured. BMI and MAMC were calculated. TSF and MAMC measurements the <5th age and gender-specific centiles were identified. Results: 168 patients [82% female, median age 61 (range 25-81)] had their BMI and MUAA assessed. 76% had limited cutaneous SSc. The remainder had diffuse cutaneous SSc. Median interval from SSc onset was 120 months (range 0-666 months). 34% were anti-centromere positive. 16% were anti-topoisomerase positive. Median BMI was 23.7 (range 15.6-39.8). 20% of patients had a BMI 20. 10% had a nondominant MAMC <5th centile; 23% had a non-dominant TSF <5th centile. Notably, 11% of patients with a BMI >20 had a TSF <5th centile. By contrast, only a minority (2%) of the patients with a BMI >20 had a MAMC <5th centile (Table 1) . Conclusion: Our study demonstrates that many patients with SSc have a low BMI, highlighting their significant risk of malnutrition. However, MUAA, particularly TSF, as an indication of malnutrition, may be misleading in patients with SSc and should not be used in isolation. Additional studies are needed to determine whether BMI changes correspond with changes in MUAA.
Conclusion

COMPARISON OF MID-UPPER ARM ANTHROPOMETRY TO BODY MASS INDEX IN PATIENTS WITH SYSTEMIC SCLEROSIS
Disclosure statement: The authors have declared no conflicts of interest. The median time from SSc onset to HPN was 113 months (range 14-389). All had small intestinal involvement. 80% had proven bacterial overgrowth. 44% had experienced at least one episode of pseudoobstruction. 16% had a small intestinal resection. Prior to HPN initiation, 6 patients failed a naso-enteric feeding trial. 10 patients had a gastrostomy or jejunostomy inserted; 7 of whom received enteral feeding for less than 1 year. The remaining 9 patients commenced HPN directly, without enteral tube feeding, because of the severity of their dysmotility/associated co-morbidity. Only 2 patients were weaned off HPN (after 8 and 29 months) following successful medical optimization. After 1 year, median BMI rose from 18.5 to 21.3. 3 patients received HPN for more than 10 years. The cumulative survivals on HPN after 1, 5 and 10 years were 75%, 37% and 23% respectively. No patients died from HPN-related complications. 16 died from causes related to their SSc. 1 died from malignancy. 8 patients survive, 7 of whom remain on HPN (median duration: 40 months, range 9-178). 9 patients were trained to manage their central venous catheters and self-administer HPN. 16 patients relied on others for their HPN administration. Reported catheter complications included non-thrombotic occlusion (0.70/1000 catheter days), sepsis (0.19/1000 catheter days) and central venous thrombosis (0.11/1000 catheter days). The sepsis rate for all HPN patients, at the same IF centre, is 0.39/1000 catheter days. No one developed IF-associated liver disease. 
RETROSPECTIVE REVIEW OF PATIENTS WITH SYSTEMIC SCLEROSIS ON HOME PARENTERAL NUTRITION
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